FBT - First Trust NYSE Arca Biotechnology Index Fund
| Previous Close | 135.21 |
| Open | 135.74 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 134.30 - 135.74 |
| 52 Week Range | 102.93 - 147.10 |
| Volume | 59,202 |
| Avg. Volume | 73,557 |
| Net Assets | 1.41B |
| NAV | 132.77 |
| PE Ratio (TTM) | N/A |
| Yield | 0.00% |
| YTD Return | 6.69% |
| Beta (3y) | 1.46 |
| Expense Ratio (net) | 0.56% |
| Inception Date | 2006-06-19 |
- ETF Trends•20 days ago
Alkermes FDA Refusal: Biotech ETFs Dragged Down
Biotechnology stocks and biotech ETFs were among the worst performing areas of the markets Monday as Alkermes (NasdaqGS: ALKS) shares plunged after the U.S. food and Drug Administration refused to review ...
- Market Realist•25 days ago
Ionis Pharmaceuticals Stock as of March 27, 2018
Analyzing Volatility in Ionis Pharmaceuticals StockIonis Pharmaceuticals
- Motley Fool•last month
The 4 Top Biotech ETFs
Investing in biotechnology has been very lucrative lately, and these funds can help you tap into the industry's success.
- InvestorPlace•last month
9 ETF Winners From 9-Year Bull Run
The bull market is now nine years old, overcoming a plethora of challenges including debt crisis, government shutdown, the Middle East conflict, geopolitical tension, Greece turmoil, China’s soft landing issues, Japan’s recession, a global slowdown, Brexit, the oil price carnage, and Trump’s protectionist stance.Source: Shutterstock
- InvestorPlace•last month
4 Hot Sector ETFs Springing Up to Rank #1
Threats of inflation, faster-than-expected interest rates, and the possibility of a trade war are playing foul in the U.S. stock market. President Trump announced his plan to impose severe tariffs of 24% on steel imports and 10% on aluminum imports “for a long period of time.” This would result in higher prices for a wide range of products thereby hurting a number of industries and overall economic growth.
- Zacks•2 months ago
4 Hot Sector ETFs Springing Up to Rank #1
A number of funds in their respective sectors have seen their Ranks surging to the top hierarchy and could make great spring picks.
- ETF Trends•3 months ago
Biotech ETFs Pop on Celgene, Juno Deal
This article was originally published on ETF Trends.com. Biotechnology sector-related ETFs surged Monday after Celgene (NasdaqGS: CELG) said it will acquire Juno Therapeutics (NasdaqGS: JUNO) to expand ...
- Market Realist•3 months ago
A Look at Ionis Pharmaceuticals’ January 2018 Valuation
What's the Word on Ionis Pharmaceuticals This January?A look at Ionis Pharmaceuticals
- Zacks•4 months ago
Sector ETF & Stock Winners 10-Years Since Great Recession
While most of the sectors have flourished over the past decade, consumer discretionary and information technology have led the way .
- Business Wire•6 months ago
Four Additional First Trust ETFs Approved for Sale in Mexican Pension Plans
First Trust Advisors L.P. a global exchange-traded fund provider and asset manager, announced that the Mexican pension funds investment regulator, La Comisión Nacional del Sistema de Ahorro para el Retiro , has approved four additional First Trust ETFs for sale to Mexican funded pensions, known as AFORES.
- Harvest Exchange•7 months ago
Gene-Editing Could Modify and Cure Disease: CRISPR vs. TALENs
The following is original research by ARK's Genomic Revolution Analyst, Manisha Samy . Genome-Editing During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in ...
- Harvest Exchange•7 months ago
A Shot in the Arm for the UK Life Sciences Industry?
Prime Minister May Looks to Bolster the Sector Earlier this year, Prime Minister Theresa May earmarked life sciences as one of five areas critical to the UK’s economic growth and commissioned a proposal on how to bolster the sector, especially as the ...
- Investor's Business Daily•7 months ago
Apple Gains As Launch Event Kicks Off; 2 Dividend Plays To Watch
Key U.S. index funds were moderately higher Tuesday as the S&P 500 rose to a new record high.
- Market Realist•7 months ago
How Gilead’s Other Products Performed in 2Q17
Apart from Gilead Sciences' (GILD) antiviral drugs portfolio, the company also includes drugs from therapeutic areas like cardiovascular, inflammation, oncology, and respiratory products in its portfolio....
- Investor's Business Daily•7 months ago
2 Hot Biotech Plays In Reach, But Is Apple Still In Buy Range?
Key U.S. index funds rallied to big gains, led by Apple's 2% jump ahead of its Tuesday product launch event.
- Market Realist•7 months ago
Nuplazid Expected to Become a Leading Central Nervous System Drug
On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.
- Market Realist•7 months ago
Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a "hold."
- Market Realist•8 months ago
Ionis Reports Revenue Growth in 2Q17
Ionis (IONS) is a biopharmaceutical company that develops and commercializes RNA-targeted therapies.
- Market Realist•9 months ago
The Rise of Amgen Stock in 2Q17
Amgen (AMGN) stock has risen ~5.8% in 2Q17, while it has risen ~17.4% year-to-date as of July 7, 2017.
- Market Realist•10 months ago
What Analysts Recommend for United Therapeutics in June 2017
Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”
- Market Realist•10 months ago
Neurocrine Biosciences: Ingrezza, Collaborations, Ratings
In April 2017, the FDA approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia.
- Zacks•10 months ago
The Zacks Analyst Blog Highlights: SPDR Technology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, BioShares Biotechnology Products ETF and SPDR Healthcare ETF
The Zacks Analyst Blog Highlights: SPDR Technology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca Biotechnology Index Fund, BioShares Biotechnology Products ETF and SPDR Healthcare ETF
- Zacks•10 months ago
Forget Big Tech, Biotech ETFs are Soaring Higher
Biotech stocks are surging of late; we discuss the reasons behind the rebound and highlight the best performing ETFs.
